Highlights
- Integrated CGM and Remote Patient Monitoring (RPM) provides superior health outcomes over 20-year and lifetime horizons compared to CGM alone or SMBG.
- The Incremental Cost-Effectiveness Ratio (ICER) for CGM with RPM is approximately $27,400 per QALY, significantly more favorable than CGM alone ($103,700 per QALY).
- CGM with RPM remains cost-effective even if real-world clinical efficacy is only 30% of that observed in specialized trials like the 4T Study.
- The strategy yields net health care savings by reducing the incidence and costs associated with long-term complications such as ESRD, CVD, and retinopathy.
Background
The management of pediatric Type 1 Diabetes (T1D) has been transformed by technology, moving from intermittent self-monitoring of blood glucose (SMBG) to continuous glucose monitoring (CGM). However, while CGM provides the data necessary for tight glycemic control, its effectiveness is often limited by the capacity of patients and caregivers to interpret and act upon that data. Remote Patient Monitoring (RPM)—where clinical teams proactively review CGM data and provide timely interventions—has emerged as a potential solution to bridge this gap. The “Teamwork, Targets, Technology, and Tight Glycemia” (4T) Study recently demonstrated that early initiation of CGM paired with RPM significantly improves glycemic outcomes in newly diagnosed pediatric patients. Despite these clinical gains, the economic viability of such resource-intensive programs remained a critical question for healthcare payers and policy experts. This review synthesizes recent evidence on the cost-effectiveness of this integrated approach within the U.S. healthcare framework.
Key Content
Methodological Framework: The Markov Model Approach
A recent comprehensive analysis (Dupenloup et al., 2026) utilized a Markov model to simulate the progression of T1D in a cohort of 5-year-old patients. The model evaluated three distinct intervention paths over 20-year, 50-year, and lifetime horizons:
- SMBG: The traditional standard of care involving finger-stick testing.
- CGM Alone: Real-time glucose monitoring without formal, proactive clinical data review.
- CGM with RPM: The integrated 4T approach, incorporating technology and proactive clinical team engagement.
The simulation tracked both acute complications—diabetic ketoacidosis (DKA) and severe hypoglycemia (SH)—and seven major chronic complications: retinopathy, neuropathy, nephropathy, cardiovascular disease (CVD), end-stage renal disease (ESRD), lower-extremity amputation, and blindness.
Clinical Efficacy and Quality of Life Outcomes
Efficacy estimates were synthesized from meta-analyses of pediatric CGM studies and the results of the 4T Study 1. The findings were stark: over a 20-year horizon, CGM alone increased quality-adjusted life years (QALYs) by only 0.09 compared with SMBG. In contrast, CGM with RPM increased QALYs by 0.37. This fourfold increase in QALY gain highlights the synergistic effect of combining advanced technology with structured clinical support. The primary driver of these gains was the reduction in the cumulative incidence of chronic microvascular and macrovascular complications due to improved HbA1c levels starting from diagnosis.
Economic Analysis and Cost-Effectiveness
From a cost perspective (2022 U.S. dollars), the interventions were evaluated with a 3% annual discount rate. Over 20 years, CGM with RPM increased total healthcare costs by $10,300 compared to SMBG. However, when calculating the Incremental Cost-Effectiveness Ratio (ICER):
- CGM vs. SMBG: $103,700/QALY.
- CGM with RPM vs. SMBG: $27,400/QALY.
In the U.S., a common willingness-to-pay threshold is $50,000 to $100,000 per QALY. These results indicate that CGM with RPM is not only more effective than CGM alone but also far more cost-effective. The higher upfront costs of the RPM intervention (staffing for data review and patient coaching) are largely offset by the averted costs of treating debilitating chronic complications later in life.
Sensitivity and Robustness Analyses
A critical component of this research was the sensitivity analysis regarding clinical efficacy. Implementation of RPM programs can vary by institution. The study found that CGM with RPM remained cost-effective even if it achieved only 30% of the clinical efficacy reported in the 4T Study. This suggests that even less-intensive versions of the program are likely to be economically viable in diverse clinical settings. Furthermore, the results remained robust across different time horizons, reinforcing the long-term value of early, aggressive intervention.
Expert Commentary
The findings by the 4T Research Team represent a paradigm shift in pediatric diabetes care. Historically, the clinical community has focused on the tools (CGM); this evidence shifts the focus to the system of care (RPM). The high cost-effectiveness of RPM ($27,400/QALY) is particularly notable because many medical interventions currently covered by insurance have much higher ICERs.
From a mechanistic standpoint, the integration of RPM addresses the behavioral and cognitive load of T1D management. By providing a “safety net” of clinical oversight, RPM allows for more aggressive insulin titration with reduced fear of hypoglycemia. However, clinicians must note that the success of RPM depends on the infrastructure for data transmission and the availability of trained personnel. While the economic model accounts for these costs, the logistical hurdle of scaling such programs across all pediatric clinics remains a challenge. There is also a significant health equity implication: if RPM is only available at well-funded tertiary centers, the disparity in outcomes between socioeconomic groups could widen, despite the technology’s inherent cost-effectiveness.
Conclusion
Integrating Remote Patient Monitoring with Continuous Glucose Monitoring for newly diagnosed pediatric T1D patients is a superior clinical strategy that is highly cost-effective under standard U.S. economic thresholds. By improving glycemic control in the critical years following diagnosis, this approach significantly reduces the long-term burden of diabetes complications. Future research should focus on identifying the most efficient delivery models for RPM to ensure these benefits can be scaled equitably across the pediatric population. Healthcare payers should consider these findings when developing reimbursement policies for telehealth and proactive diabetes management services.
References
- Dupenloup P, Chen Y, Prahalad P, Johari R, Addala A, Zaharieva DP, Lee MY, Maahs DM, Scheinker D, Brandeau ML, 4T Research Team*. Cost-Effectiveness of Continuous Glucose Monitoring With Remote Patient Monitoring in Pediatric Patients With Newly Diagnosed Type 1 Diabetes in the U.S. Diabetes care. 2026-May-01;49(5):889-897. PMID: 41879358.